|
US2572728A
(en)
|
1949-01-07 |
1951-10-23 |
American Cyanamid Co |
Hydroxybenzenesulfonamidopyra-zines and preparation of same
|
|
US2636882A
(en)
|
1950-08-11 |
1953-04-28 |
Quaker Oats Co |
Preparation of 3-pyridols from 2-acylfurans
|
|
BE758503A
(fr)
|
1969-11-07 |
1971-05-05 |
Shell Int Research |
Compositions pesticides
|
|
GB1459571A
(en)
|
1974-09-12 |
1976-12-22 |
Pfizer Ltd |
Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
|
|
JPS5762269A
(en)
|
1980-10-03 |
1982-04-15 |
Ogawa Koryo Kk |
2,3,5-trisubstituted pyrazine derivative
|
|
US4513135A
(en)
|
1982-03-05 |
1985-04-23 |
Eli Lilly And Company |
Diaryl-pyrazine derivatives affecting GABA binding
|
|
DE3242195A1
(de)
|
1982-11-15 |
1984-05-17 |
Basf Ag, 6700 Ludwigshafen |
Neue 2-aminopyrazine und verfahren zur herstellung von 2-aminopyrazinen und pyrazinen
|
|
JPH0249775A
(ja)
|
1988-05-19 |
1990-02-20 |
Nippon Soda Co Ltd |
６員環又は７員環を有する複素環化合物及びその製造方法
|
|
JPH04112877A
(ja)
|
1990-09-04 |
1992-04-14 |
Nippon Soda Co Ltd |
新規シアノピラジン誘導体及びその製造方法
|
|
EP0579835A4
(en)
|
1991-11-12 |
1994-06-01 |
Nippon Soda Co |
Wavelength conversion material for agriculture
|
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
|
GB9504854D0
(en)
|
1994-03-31 |
1995-04-26 |
Zeneca Ltd |
Nitrogen derivatives
|
|
AU713673B2
(en)
|
1996-02-07 |
1999-12-09 |
Neurocrine Biosciences Inc. |
Pyrazolopyrimidines as crf receptor antagonists
|
|
CA2293400A1
(en)
|
1997-06-13 |
1998-12-17 |
Gerald Mcmahon |
Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
|
|
WO2001016097A1
(en)
|
1999-08-27 |
2001-03-08 |
Sugen, Inc. |
Phosphate mimics and methods of treatment using phosphatase inhibitors
|
|
PL365238A1
(en)
|
2000-02-16 |
2004-12-27 |
Neurogen Corporation |
Substituted arylpyrazines
|
|
WO2003029422A2
(en)
|
2001-10-01 |
2003-04-10 |
Mount Sinai School Of Medicine |
Noonan syndrome gene
|
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
|
BR0214309A
(pt)
|
2001-11-21 |
2004-10-13 |
Upjohn Co |
Derivados aril-1,4-pirazina substituìdos
|
|
EP1492784A4
(en)
|
2002-03-28 |
2006-03-29 |
Merck & Co Inc |
SUBSTITUTED 2,3-DIPHENYLPYRIDINES
|
|
US20040116444A1
(en)
|
2002-09-12 |
2004-06-17 |
Corbett Jeffrey W. |
Substituted 1,4-pyrazine derivatives
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7157460B2
(en)
|
2003-02-20 |
2007-01-02 |
Sugen Inc. |
Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
|
|
JP2006525993A
(ja)
|
2003-05-09 |
2006-11-16 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
Ｃｒｆ１受容体拮抗剤である化合物
|
|
GB0314057D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
|
FR2856684B1
(fr)
|
2003-06-26 |
2008-04-11 |
Sanofi Synthelabo |
Derives de diphenylpyridine, leur preparation et leur application en therapeutique
|
|
CA2537916A1
(en)
|
2003-09-03 |
2005-03-31 |
Neurogen Corporation |
5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
|
|
BRPI0415185A
(pt)
|
2003-10-10 |
2006-11-28 |
Pfizer Prod Inc |
2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
|
|
CA2543644A1
(en)
|
2003-10-27 |
2005-05-06 |
Astellas Pharma Inc. |
Pyrazine derivatives and pharmaceutical use thereof
|
|
DE102004015954A1
(de)
|
2004-04-01 |
2005-11-10 |
Ina-Schaeffler Kg |
Umschlingungstrieb
|
|
WO2005095384A1
(en)
|
2004-04-01 |
2005-10-13 |
Astellas Pharma Inc. |
Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
|
|
US20050282818A1
(en)
|
2004-06-22 |
2005-12-22 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase inhibitors
|
|
AU2005322114A1
(en)
|
2004-12-23 |
2006-07-06 |
Mallinckrodt Llc |
Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
|
|
JP4873352B2
(ja)
*
|
2005-02-16 |
2012-02-08 |
シェーリング コーポレイション |
Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン
|
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
|
UA95244C2
(ru)
|
2005-06-22 |
2011-07-25 |
Плексикон, Инк. |
Соединения и способ модулирования активности киназ, и показания для их применения
|
|
EP1948827B1
(en)
|
2005-10-21 |
2016-03-23 |
The Regents of The University of California |
C-kit oncogene mutations in melanoma
|
|
CA2616147A1
(en)
|
2006-02-24 |
2007-09-20 |
Mallinckrodt Inc. |
Process for using optical agents
|
|
JP2007277097A
(ja)
|
2006-04-03 |
2007-10-25 |
Mie Univ |
発光化合物、発光方法、及びその製造方法
|
|
WO2007117699A2
(en)
|
2006-04-07 |
2007-10-18 |
University Of South Florida |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
|
|
AU2007243280A1
(en)
*
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Formulations containing pyridazine compounds for treating neuroinflammatory diseases
|
|
US7893058B2
(en)
|
2006-05-15 |
2011-02-22 |
Janssen Pharmaceutica Nv |
Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
|
PT2029602E
(pt)
|
2006-05-31 |
2010-07-08 |
Galapagos Nv |
Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
|
|
EP2029605A1
(en)
|
2006-06-06 |
2009-03-04 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
|
JP2010520238A
(ja)
|
2007-03-01 |
2010-06-10 |
マリンクロット インコーポレイテッド |
統合された光活性低分子および統合された光活性低分子使用
|
|
CN101679418A
(zh)
|
2007-04-06 |
2010-03-24 |
诺瓦提斯公司 |
用作蛋白质激酶抑制剂的[2,6]萘啶类化合物
|
|
WO2008138843A1
(en)
|
2007-05-10 |
2008-11-20 |
Galapagos N.V. |
Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
|
|
US8148369B2
(en)
|
2007-05-10 |
2012-04-03 |
Janssen Pharmaceutica Nv |
Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
|
EP2157090A4
(en)
|
2007-06-21 |
2011-09-07 |
Taisho Pharmaceutical Co Ltd |
PYRAZINAMIDE COMPOUND
|
|
WO2009020534A2
(en)
*
|
2007-08-03 |
2009-02-12 |
Schering Corporation |
Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
|
|
CA2695621A1
(en)
|
2007-08-09 |
2009-02-12 |
Merck Sharp & Dohme Corp. |
Pyridine carboxamide orexin receptor antagonists
|
|
US20090062277A1
(en)
*
|
2007-08-21 |
2009-03-05 |
Essa Hu |
Phosphodiesterase 10 inhibitors
|
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
|
AU2009308982A1
(en)
|
2008-10-30 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Pyridazine carboxamide orexin receptor antagonists
|
|
BRPI1006942A2
(pt)
|
2009-01-23 |
2016-04-12 |
Rigel Pharmaceuticals Inc |
composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
|
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
|
EP2438041A4
(en)
*
|
2009-06-01 |
2012-11-21 |
Merck Sharp & Dohme |
PYRAZINE-carboxamide-orexin receptor Antagonist
|
|
NZ713361A
(en)
*
|
2009-08-17 |
2017-06-30 |
Memorial Sloan Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
|
US8163283B2
(en)
|
2009-09-03 |
2012-04-24 |
Vancouver Biotech Ltd. |
Monoclonal antibodies against gonadotropin-releasing hormone receptor
|
|
US8673913B2
(en)
|
2009-11-13 |
2014-03-18 |
Case Western Reserve University |
SHP-2 phosphatase inhibitor
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
TW201200518A
(en)
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
WO2011143148A1
(en)
*
|
2010-05-11 |
2011-11-17 |
Sanofi |
Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
|
|
US8703768B2
(en)
|
2010-06-09 |
2014-04-22 |
Hoffmann-La Roche Inc. |
Nitrogen containing heteroaryl compounds
|
|
PT2593452T
(pt)
|
2010-07-14 |
2017-04-24 |
Novartis Ag |
Compostos heterocíclicos agonistas do receptor ip
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
WO2012149280A2
(en)
|
2011-04-29 |
2012-11-01 |
Abbott Laboratories |
Novel tricyclic compounds
|
|
CN103181918B
(zh)
|
2011-05-04 |
2014-10-29 |
厦门大学 |
脂肪酸类化合物在制备预防和治疗肝癌药物中的应用
|
|
US20150005311A1
(en)
|
2012-01-13 |
2015-01-01 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
|
JP6374384B2
(ja)
|
2012-08-07 |
2018-08-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
|
|
CA2890009C
(en)
|
2012-11-08 |
2017-11-28 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
MX359651B
(es)
|
2012-11-29 |
2018-10-05 |
Chemocentryx Inc |
Antagonistas de cxcr7.
|
|
WO2014113584A1
(en)
|
2013-01-16 |
2014-07-24 |
Rhode Island Hospital |
Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
|
|
WO2014121885A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Patent Gmbh |
Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
|
|
JP6647868B2
(ja)
|
2013-02-20 |
2020-02-14 |
ノバルティス アーゲー |
ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
|
|
US10501531B2
(en)
|
2013-03-13 |
2019-12-10 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
CN103554038B
(zh)
|
2013-06-19 |
2015-10-14 |
云南大学 |
多卤代苯腈喹唑啉酮化合物及其制备方法和用途
|
|
WO2015107494A1
(en)
*
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
JO3517B1
(ar)
*
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
ES2699351T3
(es)
*
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
US11331312B2
(en)
|
2014-04-25 |
2022-05-17 |
Memorial Sloan-Kettering Cancer Center |
Treatment of H-Ras-driven tumors
|
|
WO2016007731A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyridines and imidazopyrazines as lsd1 inhibitors
|
|
JP6759514B2
(ja)
*
|
2014-08-01 |
2020-09-23 |
ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ |
ブロモドメインに対して活性な化合物
|
|
US10472347B2
(en)
|
2014-11-18 |
2019-11-12 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with A2A antagonist properties
|
|
WO2016100116A1
(en)
|
2014-12-17 |
2016-06-23 |
Siemens Healthcare Diagnostics Inc. |
Sandwich assay design for small molecules
|
|
UY36462A
(es)
|
2014-12-23 |
2016-07-29 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos
|
|
EP3247378B8
(en)
|
2015-01-09 |
2023-08-23 |
Revolution Medicines, Inc. |
Macrocyclic compounds that participate in cooperative binding and medical uses thereof
|
|
CN107250108B
(zh)
|
2015-02-05 |
2020-11-27 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
EP3277689B1
(en)
|
2015-04-03 |
2019-09-04 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
WO2016203405A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
US10287266B2
(en)
*
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
US10426842B2
(en)
|
2015-07-15 |
2019-10-01 |
The Curators Of The University Of Missouri |
Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
|
|
EP4242304A3
(en)
|
2015-10-01 |
2024-02-07 |
Revolution Medicines, Inc. |
Methods and reagents for analyzing protein-protein interfaces
|
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
|
GB201604970D0
(en)
*
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
GB201604969D0
(en)
*
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
MX388576B
(es)
|
2016-06-07 |
2025-03-20 |
Jacobio Pharmaceuticals Co Ltd |
Derivados heterociclicos novedosos utiles como inhibidores de shp2.
|
|
WO2017216706A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
EP4302834A3
(en)
|
2016-07-12 |
2024-07-17 |
Revolution Medicines, Inc. |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
|
|
WO2018057884A1
(en)
|
2016-09-22 |
2018-03-29 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
TW202500565A
(zh)
|
2016-10-24 |
2025-01-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
CA3048340A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Novartis Ag |
Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
|
|
JP7240319B2
(ja)
|
2017-01-23 |
2023-03-15 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としての二環式化合物
|
|
KR20190110588A
(ko)
*
|
2017-01-23 |
2019-09-30 |
레볼루션 메디슨즈, 인크. |
알로스테릭 shp2 억제제로서의 피리딘 화합물
|
|
EA202190196A1
(ru)
|
2017-03-23 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
IL269779B2
(en)
|
2017-04-05 |
2026-04-01 |
Revolution Medicines Inc |
Methods and reagents for the analysis of protein-protein interfaces
|
|
CA3058953A1
(en)
|
2017-04-05 |
2018-10-11 |
Revolution Medicines, Inc. |
Compounds that participate in cooperative binding and uses thereof
|
|
EP3630770B1
(en)
|
2017-05-26 |
2024-08-28 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
CA3074690A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions and methods for treating cancer
|
|
TW201930292A
(zh)
|
2017-10-12 |
2019-08-01 |
美商銳新醫藥公司 |
作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
|
|
JP7361693B2
(ja)
|
2017-12-15 |
2023-10-16 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としての多環式化合物
|
|
CN110156786B
(zh)
|
2018-02-13 |
2022-06-03 |
青煜医药研发(上海)有限公司 |
嘧啶并环化合物及其制备方法和应用
|
|
JP7335882B2
(ja)
|
2018-02-13 |
2023-08-30 |
ブルーレイ セラピューティクス （シャンハイ） カンパニー，リミティド |
ピリミジン縮合環式化合物及びその製造方法、並びに使用
|
|
RU2020133727A
(ru)
*
|
2018-03-21 |
2022-04-21 |
Сучжоу Пухе Биофарма Ко., Лтд. |
Ингибиторы shp2 и их применение
|
|
MX2020010719A
(es)
|
2018-04-10 |
2020-11-06 |
Revolution Medicines Inc |
Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2.
|
|
MX2020011565A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
|
|
IL312291A
(en)
|
2018-05-01 |
2024-06-01 |
Revolution Medicines Inc |
C-26-linked rapamycin analogs as MTOR inhibitors
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CR20210175A
(es)
*
|
2018-09-18 |
2021-06-01 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
JP2022508651A
(ja)
|
2018-10-08 |
2022-01-19 |
レヴォリューション・メディスンズ，インコーポレイテッド |
癌を処置するためのｓｈｐ２阻害剤組成物および方法
|
|
JP2022506887A
(ja)
|
2018-11-07 |
2022-01-17 |
シャンハイ リンジーン バイオファーマ カンパニー リミテッド |
窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
EP3889153A4
(en)
|
2018-11-30 |
2022-09-07 |
Tuojie Biotech (Shanghai) Co., Ltd. |
PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF
|
|
US20220073521A1
(en)
|
2018-11-30 |
2022-03-10 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
|
|
BR112021012057A2
(pt)
|
2018-12-21 |
2021-10-19 |
Revolution Medicines, Inc. |
Compostos que participam de ligação cooperativa e usos dos mesmos
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|